German biotechnology company BioNTech SE (Nasdaq:BNTX) has said it will expand an ongoing clinical trial programme to develop new vaccines and patterns of administration for better protection against the dominant Omicron COVID-19 variant, Reuters news agency reported on Wednesday.
According to the company, this addition of cohorts to a trial programme initially unveiled in January 2022 comes as global infection numbers are on the rise and protection against infection from its established Comirnaty vaccine, co-developed with Pfizer (NYSE:PFE), has waned.
BioNtech plans to spend between EUR1.4bn to EUR1.5bn on research and development this year, thanks to a EUR10.3bn net income in 2021.
The company also reiterated its 2022 vaccine revenue guidance of between EUR13bn to EUR17bn.
Bruker Corporation to acquire ELITechGroup for EUR870m, strengthening MDx portfolio
Perrigo announces quarterly dividend increase
Bruker expands Preclinical Imaging Portfolio with acquisition of Spectral Instruments Imaging
Fusion Antibodies announces receipt of follow-on project and provides R&D update
Alvotech reports positive results for AVT03, potential biosimilar to Prolia and Xgeva
Biosenic finalises agreement with Phebra for oral arsenic troxide development